LF111 or drospirenone

Phase 3Small molecule

IInsud Pharma

LF111 or drospirenone is one of 28 small molecule programs targeting Adolescent. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdolescentRecruiting

AdolescentPhase 3

Recruiting

Competition

Competitive Landscape

32 competitors in Adolescent

#DrugCompanyPhaseTrials

Zoloft

VViatris Specialty LLC

Approved

4 2

Fanapt

VVanda Pharmaceuticals

Approved

2 3

Abilify

Otsuka

Approved

2 4

Sunlenca

Gilead

Phase 3

2 5

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

8 6

Lithobid

SSolvay Pharmaceuticals

Phase 3

2 7

Brintellix

Takeda

Phase 2

1 8

Camptosar

Pfizer

Phase 2

1 9

Cymbalta

Jazz Pharmaceuticals

Phase 2

1 10

Valdoxan

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Adolescent

NCT05303636

Clinical

Trials by Indication[1]

Adolescent1 trial

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Recruiting·IInsud Pharma·Phase 4·NCT05303636·1,710 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LF111 or drospirenone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LF111 or drospirenone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LF111 or drospirenone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Insud Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInsud Pharma

LF111 or drospirenone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Adolescent1 trial

References

Drug Info

Quick Facts

Related News